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by computed tomography: do anticoagulants and
antiplatelet agents have a role?
Olivier Risch1, Agaicha Alfidja1, Aurelien Mulliez2, Anderson H Amani3, Louis Boyer1, Lionel Camilleri3
and Kasra Azarnoush3,4*Abstract
Purpose: Bleeding is the most common and most serious complication of anticoagulant (AC) and antiplatelet
agents (APA) which are increasingly used in every day practice. The aim of this study was to enlist and analyze the
most severe bleeding events revealed during computed tomography scanner (CT scan) examinations over a 1-year
period at our University Hospital and to evaluate the role of ACs and APAs in their occurrence.
Methods: This descriptive monocentric retrospective study included all patients who benefited from an emergency
CT scan with a diagnosis of severe non-traumatic bleeding. Patients were divided into two groups: those treated
with ACs and/or APAs, and those not treated with ACs or APAs.
Results: After applying the inclusion criteria, 93 patients were enrolled. Sixty-one patients received an anticoagulant
or antiplatelet treatment, and 32 did not receive any AC or APA therapy. Seventy nine percent presented with an
intracranial hemorrhage, 17% with a rectus sheath or iliopsoas bleeding or hematoma, and 4% with a quadriceps
hematoma. Only patients who received ACs or APAs suffered a muscular hematoma (p <0.0001). Among patients
treated with vitamin K antagonists, 6/43 (14%), had an international normalized ratio (INR) higher than the therapeutic
range (INR >3).
Conclusions: In our series, intracranial hemorrhage was preponderant and muscular hematomas occurred exclusively
in patients treated with ACs and/or APAs. This study needs to be extended to evaluate the impact of new
anticoagulant and antiplatelet agents.
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Bleeding is regarded as severe if it has hemodynamic
consequences that require transfusion or a hemostatic
therapeutic procedure, if vital or functional prognosis is
compromised due to its location, or if it cannot be
controlled by the usual means. When none of these criteria
is present, hemorrhage is qualified as non-severe [1].
Anticoagulants (AC) are the treatment for many
pathological conditions, such as venous thromboembolic
disease, atrial fibrillation, as well as for patients with* Correspondence: kazarnoush@chu-clermontferrand.fr
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unless otherwise stated.mechanical heart valve prosthesis. Although their efficacy
has been widely acknowledged, these drugs can lead to
complications, the most frequent and severe of which are
hemorrhagic events [1].
Currently, more than 900,000 patients receive vitamin-K
antagonists (VKA) in France [2]. VKAs are responsible for
most iatrogenic complications [3]. In France, the cost of
these complications is more than 300 million Euros per
year [3] and anticoagulant-related hemorrhagic accidents,
especially directly caused by VKAs, are responsible
for almost 20.000 hospitalizations per year, with a 5/100
patient-year incidence of severe bleeding events and a
1/100 patient-year incidence of fatal events.
Besides anticoagulants (AC), antiplatelet agents (APA)
also induce an important risk for major bleeding. This risktd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 Indications and results of CT-scans in patients
with a hemorrhagic event
Indications and results of CT-scans Number Percentage
Consciousness disorders 39 42
Headache 13 14
Focal neurological signs 59 63
Abdominal pain 15 16
Anemia 21 24
Thigh swelling 4 4
Results
Cerebral CT-scan (intracranial hemorrhage) 73 78
Subarachnoid hemorrhage 5
Peri-cerebral hematoma 12
Intraparenchymal hematoma 62
Intraventricular hemorrhage 34
Cerebral herniation 36
Abdominal and lower-limb CT-scan
(muscular hematoma)
20 22
Rectus abdominis hematoma 11
Iliopsoas hematoma 5
Quadriceps hematoma 4
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agents are used as a bitherapy [4].
Many factors contribute to the hemorrhagic complica-
tions that can occur under anticoagulant therapy [4,5].
The most important factor is age, with a nearly 50%
increased risk of severe hemorrhage per decade in
those aged more than 40 years. Arterial hypertension
is also a significant risk factor [4-6].
Despite the standardization of laboratory procedures,
agreement on therapeutic ranges and the introduction
of new anticoagulants into the therapeutic arsenal, the
occurrence of hemorrhagic events remains significant [7-9].
The aim of our study was to register and analyze the
most severe bleeding events revealed during CT scan
examinations over a 1-year period at our University
Hospital and to evaluate the role of ACs and APAs in
their occurrence.
Methods
Patients
Between April 1, 2011 and March 31, 2012, we performed
a monocentric retrospective study that included all
patients who had undergone a CT scan for a non-traumatic
severe hemorrhage. Exclusion criteria were represented
by all suspected traumatic contexts, hemorrhages caused
by an underlying tumor, a vascular malformation, or a
postoperative bleeding.
During this period, 93 patients were included (50
males, 43 females), mean age 76 ± 11 years, who
had been referred by various departments: emergency
(n = 75), cardiology (n = 7), recovery unit (n = 5), rheuma-
tology (n = 2), infectious-disease department (n = 2), and
internal medicine (n = 2).
Seventy-three patients underwent a cerebral, 16 an
abdominal, and 4 a lower-limb CT scan. Data were
collected using Xplore Exploitation software, version
6.2.814 (EDL, Santé La Seine sur Mer, France), which
records all reports from CT scans performed in our
Center (22,076 over this period), and this information was
then complited with the patients’ hospital-examination
files. The studied parameters are listed in Table 1.
The 93 patients were divided into two groups: group 1,
those who did not received ACs or APAs (n = 32) and
group 2, those who were treated with ACs and/or APAs
(n = 61) (Table 2). Details on the AC and APA treatments
are presented in Table 3. Thirty eight patients re-
ceived ACs, 16 received APAs, 6 received both ACs
and APAs, and one patient received two APAs. The
AC and/or APA indications were atrial fibrillation
(39%), thromboembolic disease (13%), coronary-artery
disease (12%), mechanical prosthesis (5%), and a previous
history of stroke (5%).
Anticoagulation reference thresholds for the international
normalized ratio (INR) were between 2.5 and 3.5 for mitralmechanical prosthesis and between 2 and 3 for the other
indications.
This descriptive, retrospective monocentric study
was conducted according to ethical principles for medical
research involving human subjects in French university
hospitals [10].Statistical analyses
The statistics were computed using STATA V10 software
(Stata Corp, College Station, Texas, USA). Data are
expressed as frequencies and associated percentages for
categorical data, and as means ± standard deviations for
continuous data.
The categorical data from the two treatment
groups were compared using the chi-squared test (or
Fisher’s exact test, if necessary). Continuous data
were compared using Student’s t-test (or the Kruskal–
Wallis test, if necessary), normality was verified by the
Shapiro–Wilk test and homoscedasticity by the Fisher–
Snedecor test.
The risk ratio, for patients who received AC or APA, for
a cerebral hemorrhage and subsequent cerebral hernia-
tion, a rectus sheath, iliopsoas bleeding, or a quadriceps
hematoma were shown with their corresponding 95%
confidence intervals.
All tests were two-sided, with the type 1 error set
at α = 0.05.
Table 2 Comparison between patients treated with
anticoagulants (AC) or antiplatelet agents (APA) and
those not treated with either
Group 1: Group 2: p-value
Not treated:
n = 32
AC or APA:
n = 61
Intracranial hemorrhage 32 (100) 41 (67) NA
Cerebral herniation (mm) 7.1 ± 2.7 9.8 ± 4.6 0.04
Muscular hematoma 0 (0) 20 (33) <0.0001
Rectus abdominis,
iliopsoas hematoma
0 (0) 16 (24) 0.001
Quadriceps hematoma 0 (0) 4 (7) 0.30
Muscular hematoma (mL) NA 363 ± 349 NA
Anemia (Hb <10 g/dL) 3 (3) 18 (30) 0.02
Hematocrit (%) 39.3 ± 6 35.6 ± 8.2 0.04
Blood platelets 221 ± 64 247 ± 88 0.28
Transfusion of globular sediment 1 (3) 7 (11) 0.17
Death 5 (15) 17 (28) 0.19
Delay between CT-scan and
death (days)
13.4 ± 21.1 7.8 ± 19.9 0.04
In-hospital stay period of
surviving patients (days)
27.7 ± 34.3 19.8 ± 26.4 0.35
Data are mean ± standard deviation, median (interquartile range) or number (%).
Abbreviations: mm millimeter, mL milliliter, g/dL gram per deciliter,
NA not applicable.
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According to international guidelines and our university
hospital’s heart-surgery department’s recommendations
[4,11,12] the indications for AC and APA treatments were
all justified. APA treatments were prescribed mainlyTable 3 Prescribed anticoagulant and antiplatelet agents
Anticoagulant treatments and
antiplatelet agents
Number Percentage
Anticoagulants 37 40
Acenocoumarol 8
Fluindione 21
Coumadin 4
Unfractionated heparin 1
Low molecular weight heparin 3
Antiplatelet agents 17 18
Aspirin 13
Ticlopidine 1
Clopidogrel 3
Antiplatelet bitherapy 1 1
Aspirin, clopidogrel 1
Anti-vitamin-K + antiplatelet agents 6 6
Fluindione + aspirin 5
Coumadin + aspirin 1for coronary and/or peripheral arteriosclerosis; ACs,
unfractionated heparin, Low Molecular Weight Heparin
(LMWH) and VKAs were prescribed for thromboembolic
disease, atrial fibrillation or in postoperative orthopedic
patients.
Four patients had an INR between 3 and 4, one patient
between 4 and 6, and another had a ratio >6. Among
these patients, 2 patients had a muscular hematoma and
4 patients had an intracranial hemorrhage. Comparisons
between patients treated and not treated by AC and
APA are listed in Table 2.
Muscular hematoma occurred in 22% of cases (n = 20),
among which 17% (n = 16) were of the rectus sheath
or iliopsoas, and 4% (n = 4) were quadriceps hemato-
mas. Muscular bleedings and hematomas occurred
exclusively in patients treated by AC or APA. This
difference was statically significant (p <0.0001)
(Table 2).
All patients (n = 4) with a quadriceps hematoma received
an anticoagulation treatment (AC exclusively in 3 patients,
and AC + APA in 1 case) (Table 4). Five cases of
iliopsoas hematomas were recorded (all in patients
treated by AC), and 11 patients had a rectus sheath
hematoma (9 received AC, 1 had APA, and 1 had a
bitherapy of AC + APA) (Table 4). The estimated risk
of soft tissue hematoma was 3.9 [1-15] in patients who
received AC compared to patients treated by antiplatelet
therapy (Figures 1 and 2).
The average muscular hematoma volume was 363 ±
249 mL, and was associated with a statistically significant
decrease in hemoglobin and hematocrit (p 0.02 and 0.04,
respectively) (Table 2).
An intracranial hemorrhage (n = 73) was the most
common bleeding event, 78% of the observed bleedings
(0.03% of the total 2274 emergency cerebral CT scans
performed during this period). A cerebral hemorrhage
was observed in 67% (n = 41) of patients treated with
AC and/or APA (Table 2).
Among patients with an intracranial hemorrhage, 32
(44%) received neither AC nor APA treatment, 21 had a
single AC treatment, 15 had a single antiplatelet therapy,
4 had a bitherapy (AC + APA), and 1 had a double anti-
platelet therapy (Table 4).
Cerebral herniation, estimated by the displacement of
medial brain structures (Figure 3), was significantly more
important in patients treated by AC and/or APA (9.8 ±
4.6 mm) compared to group 1 patients (7.1 ± 2.7 mm;
p = 0.04). The risk of cerebral herniation was higher in
patients who received AC compared to patients who
received a single APA therapy (62% vs. 31%, respectively,
RR = 2.3 [0.9–5.7]).
Among the 93 patients, 22 died (24%). In 19 cases
(86%) the cause of death was an intracranial hemorrhage
and of these, 14 (74%) were treated with AC or APA.
Table 4 Incidence of hemorrhages with the different treatments: anticoagulants (AC) and/or antiplatelet agents (APA),
or no drug therapy
Not treated: n = 32 Only AC: n = 38 APA: n = 16 AC + APA: n = 6 Double APA: n = 1
Intracranial hemorrhage 32 (100) 21 (55) 15 (94) 4 (67) 1 (100)
Muscular hematoma: n = 20 0 (0) 17 (45) 1 (6) 2 (33) 0 (0)
Quadriceps (n = 4) 0 (0) 3 (8) 0 (0) 1 (17) 0 (0)
Rectus abdominis (n = 11) 0 (0) 9 (24) 1 (6) 1 (17)
Iliopsoas (n = 5) 0 (0) 5 (13) 0 (0) 0 (0) 0 (0)
Cerebral-hematoma volume (mL) 42.9 ± 45.5 65.8 ± 46.4 28 ± 37.7 23.3 ± 44.5 0(0)
Transfusion: n = 8 1 (3) 7 (18) 0 (0) 0 (0) 0 (0)
Anemia (Hb <10 g/dL): n = 21 3 (9) 15 (39) 1 (6) 2 (33) 0 (0)
Hematocrit (%) 39.3 ± 6 33.8 ± 9.2 39.4 ± 4.2 34.9 ± 7.9 MD
Deaths: n = 22 5 (16) 13 (34) 4 (25) 0 (0) 0 (0)
Delay between CT-scan and death (days) 13.4 ± 21.1 2.8 ± 5 24 ± 39.5 0 (0) 0 (0)
In-hospital stay (days) 15 [3 – 37] 11.5 [6 – 19.5] 12 [6 – 24] 15 [4 – 78] 2 [2 – 2]
Data are mean ± standard deviation, median (interquartile range) or number (%). MD: Missing Data.
Abbreviations: mm millimeter, mL milliliter, g/dL gram per deciliter, NA not applicable.
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2 patients compared with group 1: 7.8 ± 19.9 vs. 13.4 ±
21,1 days, p = 0.04 (Table 2) and it was even shorter for
patients who received AC (2.8 ± 5 days) when compared
to all other treatments. Patients who had a bitherapy
(AC + APA or APA + APA) were all alive at the end of
this study (Table 4).Discussion
In our series, which included patients who had suffered a
severe hemorrhage detected by CT scan, the intracranial
location was predominant. In addition, these intracranial
hemorrhages were more severe when patients received
AC or APA therapy. Muscular bleedings and hematomasFigure 1 Abdominal CT scan. Hematoma of the rectus abdominis
(White arrow).were not observed in patients who did not receive any AC
or APA.
In our patient population, the main fatal hemorrhagic
event was intracranial hemorrhage (86%). In France
these account for 10–15% of the total number of cere-
brovascular events, 10–20 cases per 100,000 inhabitants
[6]. Their incidence per year is between 0.3 and 0.6%.
Palareti et al., [13] in a series that included severe as
well as minor hemorrhages, reported 153 hemorrhagic
complications (7.6 per 100 patient-years), of which
five were fatal (all cerebral hemorrhages, 0.25 per 100
patient-years), 23 were major (1.1), and 125 were
minor (6.2).
Our study did not find any significant difference in the
occurrence of intracranial hemorrhage depending onFigure 2 Abdominal CT scan. Hematoma of the left iliopsoas
(White arrow).
Figure 3 Cranial CT scan. Right parietal occipital hematoma with
cerebral oedema and left displacement of the medial brain
structures (Black arrow).
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worsening elements of a cerebral hemorrhage, such as
the volume of the cerebral hematoma, were statistically
significant in patients receiving ACs.
Cucchiara et al.’s study [14] confirms this finding. In
their series, the initial volume, the progression, and the
mortality rate from intracranial hemorrhage were greater
in patients who received VKAs compared to those who
did not receive ACs.
Tonolini et al. [15] reported that bleeding occurred in
almost every muscle group in patients treated with ACs
or APAs. On CT scan, the appearance of muscular
hemorrhages depends on its location, and bleeding rate.
Rectus sheath and iliopsoas are the most common
locations. Patients usually complain with acute abdominal
pain and distension, associated with a fall in hematocrit
and often a hypovolemic shock. In our series, severe
muscular hematomas that required a CT scan occurred
exclusively in patients who had received AC or APA
therapy.
Venous thromboembolic disease and prevention of
cardiac arterial emboli during atrial fibrillation are the
two main indications for prescribing ACs [1,4,16]. In our
study, atrial fibrillation and thromboembolic venous
disease were the most frequent indications, accounting
for, respectively, 38.5% and 13% of the cases. In a study
that included 188,740 elderly patients (aged >65 years),
Van Walraven et al. [17] reported that 10,020 people(5.3%) were treated with VKAs (3.5% of the total popula-
tion). People who received ACs had a mean age of 77 years,
and 50% were men. They spent 26.7% of their VKA
exposure time with an INR <2 and 14.2% of the time
with an INR > 3. They had an overall hemorrhagic rate of
6% per year. Bleeding rates increased significantly when
INR exceeded 3. As reported by Butchart [17] important
INR variations are as important as the high level of INRs
to explain some hemorrhagic accidents due to vitamin k
antagonists and only a careful INR control with dedicated
devices can decrease bleeding complications due to this
variations [18].
Old age is a risk factor for hemorrhagic bleedings in
patients receiving ACs or APAs [1,4,16,19], particularly
in those aged >75 years, but also for patients with a prior
history of intracranial hemorrhage [19].
Many studies show that there is a high association
between age and hemorrhagic risk. In our series,
cerebral hemorrhagic events occurred in 62.3% of patients
aged >65 years, but there was no statistically significant
difference in younger patients. Similarly, the role of
arterial hypertension, as well as described by some authors
[5,6], was not evidenced in our experience. This could be
related to our study population, which included only
severe hemorrhagic events detected by CT scan. After
AC treatment, arterial hypertension is the second most
important risk factor for intracranial hemorrhage
occurrence [20,21]. Alcohol and tobacco are other risk
factors [20].
Study limitations
This descriptive study is a collection of severe hemorrhagic
events, detected by a CT-scan in our Center, without a
comparative control population. In addition, our selection
method, which only included those who benefited from a
computerized CT scan, could have excluded patients with
milder hemorrhagic events which did not require a CT
scan, and also rapidly mortal hemorrhages. The timeframe
of our monocentric study was too short to allow exhaustive
analysis. A multicenter study with a longer follow-up period
is needed to confirm our preliminary results.
Conclusion
Severe hemorrhages are preponderantly intracranial and
have a high mortality rate, regardless of the patient’s expos-
ure to anticoagulant or antiplatelet agents. This study con-
firms that muscular and soft-tissue hemorrhagic events
exclusively occur in patients who received AC and/or APA
therapies. Further investigations are needed to monitor the
effects of new anticoagulant and antiplatelet agents.
Abbreviations
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